Mission Bio announced that it has entered into an agreement with Fulgent Genetics. Fulgent Genetics is now able to offer single-cell multi-omics on the Tapestri Platform on its fully customizable menu of services, including whole genome, whole exome, RNA sequencing, tumor profiling, methylation sequencing, liquid biopsy, single-cell sequencing, spatial biology, and pathology services to support its growing pharma client demands. Additionally, Fulgent Genetics will evaluate the Tapestri Platform for applications in clinical development to streamline the drug development and approval process.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FLGT:
- Fulgent Genetics price target lowered to $35 from $40 at Piper Sandler
- Fulgent Genetics price target lowered to $45 from $50 at Credit Suisse
- Fulgent Genetics launches new Beacon787 expanded carrier screening panel
Questions or Comments about the article? Write to editor@tipranks.com